S&P 500
7,660.64
-96.53
-1.24%
Dow
52,709.56
-146.53
-0.28%
Nasdaq
26,120.23
-582.62
-2.18%
NYSE Composite
24,136.41
-116.71
-0.48%
Russell 2000
2,767.42
-13.60
-0.49%
VIX
19.18
+2.50
+14.99%
ANAB · AnaptysBio, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
$47.90
-0.10
(-0.21%)
● Market open
DAY'S RANGE
$47.90
$47.34
$47.90
52-WEEK RANGE
$47.90
$20.18
$72.36
What's happening
- ANAB is down 0.21% today, trading at $47.90. — Live quote
- Volume today (5,996) is well below its 3-month average of 589,580. (Finnhub fundamentals)
- Reports earnings on 2026-11-10 (after market close), 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.07 actual vs. $0.00 estimated (+2158.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 9
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ANAB
+40.56%
vs S&P 500
+27.79%
1-YEAR RETURN
ANAB
+93.15%
vs S&P 500
+78.59%
6-MONTH RETURN
ANAB
+1.86%
3-MONTH RETURN
ANAB
-15.49%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.07
Est. $0.00
BEAT +2158.1%
2026-04-26 (Q1 2026)
$-1.84
Est. $-0.62
MISS -198.7%
2026-01-26 (Q4 2025)
$1.58
Est. $0.96
BEAT +65.0%
2025-10-26 (Q3 2025)
$0.52
Est. $-1.47
BEAT +135.4%
Valuation Measures & Ratios
Enterprise Value4$1.55B
Forward P/E549.51
PEG Ratio6—
Price / Sales (TTM1)6.01
Price / Book7188.81
EV4 / Revenue6.53
EV4 / EBITDA11.56
Profit Margin82.37%
Operating Margin56.36%
Return on Equity (ROE8)894.97%
Return on Assets (ROA9)57.39%
Avg Volume (3M)589,580
Quarterly history (5 periods)
| Measure | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 |
|---|---|---|---|---|---|
| Market cap | $1.06B | $592.9M | $425.8M | $380.4M | — |
| P/E | -9.19 | -6.20 | -2.70 | -2.34 | — |
| Price/Sales | 7.00 | 3.79 | 4.68 | 5.01 | — |
| Price/Book | 83.45 | -20.16 | -9.52 | 11.18 | — |
| EV/Revenue | 5.37 | 3.09 | 4.19 | 3.71 | — |
| EV/EBITDA | -15.36 | -11.73 | -3.28 | — | — |
| ROE | -907.90% | 325.32% | 352.02% | -478.46% | — |
| ROA | -35.10% | -27.10% | -46.97% | -38.57% | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short5,236,151
Change from Prior Settlement-3.70%
% of Float—
Days to Cover (Short Ratio)8.19
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 23.5% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 82.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is +93.2%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ANAB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Sep '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.6M | $76.3M | $22.3M | $27.8M | $30.0M | $11.0M | $7.2M | $3.3M |
| Operating income | -$34.6M | $34.7M | -$26.2M | -$27.5M | -$22.8M | -$40.3M | -$42.2M | -$37.7M |
| Net income | -$52.9M | $15.1M | -$38.6M | -$39.3M | -$32.9M | -$46.7M | -$43.9M | -$37.3M |
| EPS (diluted) | $-1.84 | $0.52 | $-1.34 | $-1.28 | $-1.14 | $-1.71 | $-1.64 | $-1.41 |
| EPS (basic) | $-1.84 | $0.54 | $-1.34 | $-1.28 | $-1.14 | $-1.71 | $-1.64 | $-1.41 |
| Operating margin | -$136 | $45 | -$118 | -$99 | -$76 | -$368 | -$588 | -$1.1K |
| Net margin | -$207 | $20 | -$174 | -$142 | -$109 | -$425 | -$612 | -$1.1K |
Balance sheet
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $329.7M | $364.4M | $353.1M | $335.2M | $422.1M | $483.8M | $493.4M | $427.4M |
| Stockholders' equity | $12.7M | $37.2M | -$29.4M | -$44.7M | $34.0M | $70.9M | $84.4M | $9.9M |
| Total current assets | $316.1M | $350.2M | $330.6M | $291.9M | $363.1M | $431.9M | $448.7M | $367.4M |
| Total current liabilities | $41.7M | $38.6M | $38.1M | $35.5M | $44.0M | $45.4M | $43.9M | $40.4M |
| Cash & equivalents | $248.5M | $238.2M | $109.8M | $44.3M | $98.6M | $123.1M | $191.6M | $71.8M |
| Accounts receivable | $25.7M | $33.9M | $75.7M | $21.4M | $17.9M | $40.8M | $12.2M | $9.0M |
| Property, plant & equipment | $1.3M | $1.4M | $1.5M | $1.6M | $1.7M | $1.8M | $1.7M | $1.8M |
| Other non-current assets | $256.0K | $256.0K | $256.0K | $256.0K | $256.0K | $256.0K | $256.0K | $256.0K |
| Accounts payable | $7.5M | $3.9M | $2.9M | $3.3M | $6.1M | $4.0M | $3.6M | $4.9M |
| Accrued liabilities | $32.1M | $32.7M | $33.2M | $30.2M | $36.0M | $39.5M | $38.4M | $33.7M |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $29.0K | $28.0K | $28.0K | $28.0K | $30.0K | $30.0K | $30.0K | $27.0K |
| Retained earnings | -$825.4M | -$772.6M | -$822.2M | -$837.3M | -$798.7M | -$759.3M | -$737.5M | -$704.7M |
| Accumulated other comprehensive income (loss) | -$146.0K | -$24.0K | $47.0K | -$6.0K | $161.0K | $305.0K | $759.0K | -$415.0K |
Cash flow
| Line item | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.9M | $98.0M | -$27.4M | -$40.2M | -$10.7M | -$66.7M | -$10.1M | -$21.3M |
| Investing cash flow | $35.0M | $73.5M | $103.3M | $36.4M | $14.8M | -$29.4M | $58.6M | -$2.4M |
| Financing cash flow | $1.2M | -$43.1M | -$10.4M | -$50.5M | -$28.6M | $27.6M | $71.2M | $41.9M |
| Free cash flow | -$25.9M | $98.0M | -$27.4M | -$40.3M | -$10.7M | -$66.9M | -$10.1M | -$21.4M |
| Capital expenditures | $17.0K | $1.0K | $12.0K | $39.0K | $35.0K | $263.0K | $35.0K | $33.0K |
| Depreciation & amortization | $130.0K | $131.0K | $140.0K | $142.0K | $146.0K | $145.0K | $144.0K | $154.0K |
| Share-based compensation | $14.2M | $8.5M | $9.2M | $9.2M | $9.2M | $8.2M | $8.2M | $7.5M |
| Purchases of investments | $0 | $0 | $19.7M | $54.2M | $122.5M | $120.9M | $51.3M | $149.2M |
| Share repurchases | $0 | $3.4M | $9.7M | $51.1M | $4.4M | $456.0K | $0 | $0 |
| Tax withholding on stock comp | $0 | $0 | $0 | $0 | $1.5M | $0 | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M |
| Operating income | $47.9M | -$114.9M | -$164.4M | -$115.2M | -$56.8M |
| Net income | -$13.2M | -$145.2M | -$163.6M | -$128.7M | -$57.8M |
| EPS (diluted) | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 |
| EPS (basic) | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 |
| Operating margin | $20 | -$126 | -$958 | -$1.1K | -$90 |
| Net margin | -$6 | -$159 | -$954 | -$1.3K | -$91 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M | $643.1M |
| Stockholders' equity | $37.2M | $70.9M | $88.1M | $262.1M | $356.4M |
| Total current assets | $350.2M | $431.9M | $406.8M | $447.2M | $553.9M |
| Total current liabilities | $38.6M | $45.4M | $37.4M | $26.1M | $16.1M |
| Cash & equivalents | $238.2M | $123.1M | $36.0M | $71.3M | $495.7M |
| Accounts receivable | $33.9M | $40.8M | $6.9M | $1.4M | $876.0K |
| Property, plant & equipment | $1.4M | $1.8M | $2.1M | $2.1M | $2.3M |
| Other non-current assets | $256.0K | $256.0K | $256.0K | $256.0K | $256.0K |
| Accounts payable | $3.9M | $4.0M | $4.7M | $2.8M | $1.7M |
| Accrued liabilities | $32.7M | $39.5M | $31.0M | $21.6M | $12.9M |
| Other current liabilities | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $28.0K | $30.0K | $27.0K | $29.0K | $28.0K |
| Retained earnings | -$772.6M | -$759.3M | -$614.1M | -$450.5M | -$321.8M |
| Accumulated other comprehensive income (loss) | -$24.0K | $305.0K | -$797.0K | -$5.2M | -$422.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $19.7M | -$135.3M | -$120.8M | -$73.6M | -$45.9M |
| Investing cash flow | $228.0M | $95.4M | $144.8M | -$394.8M | $38.8M |
| Financing cash flow | -$132.6M | $127.1M | -$59.3M | $44.0M | $252.3M |
| Free cash flow | $19.6M | -$135.7M | -$121.6M | -$74.0M | -$47.3M |
| Capital expenditures | $87.0K | $358.0K | $807.0K | $358.0K | $1.4M |
| Depreciation & amortization | $559.0K | $606.0K | $652.0K | $675.0K | $619.0K |
| Share-based compensation | $36.1M | $34.0M | $33.2M | $27.4M | $15.3M |
| Purchases of investments | $196.4M | $380.4M | $303.9M | $802.5M | $118.7M |
| Share repurchases | $68.6M | $456.0K | $50.0M | $0 | $0 |
| Tax withholding on stock comp | $1.5M | $7.5M | $0 | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ANAB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-06 to 2026-10-01
Recent transactions
- Insiders have net sold 5,000 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: RENTON HOLLINGS (Reporting person) — Option exercise of 5,000 shares on 2026-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)5,000 sh(1 txns)
Net Shares-5,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| RENTON HOLLINGS | Reporting person | Option exercise | 2026-10-01 | 5,000 |
| Orwin John A | Reporting person | Option exercise | 2026-09-15 | 1,300 |
| Schmid John P. | Reporting person | Option exercise | 2026-06-15 | 6,030 |
| ANAPTYSBIO, INC | Reporting person | Other acquisition/disposition | 2026-04-20 | 100 |
| Faga Daniel | President, CEO | Open market sale | 2026-03-27 | 510 |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Option exercise | 2026-02-11 | 10,000 |
| Marquet Magda | Reporting person | Option exercise | 2026-01-15 | 11,000 |
| Lizzul Paul F. | Chief Medical Officer | Open market sale | 2026-01-08 | 3,650 |
| MULROY DENNIS | CHIEF FINANCIAL OFFICER | Open market sale | 2026-01-08 | 2,515 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | RENTON HOLLINGS | Reporting person | Option exercise | 5,000 | $18.03 |
| 2026-10-01 | RENTON HOLLINGS | Reporting person | Open market sale | 5,000 | $49.87 |
| 2026-09-15 | Orwin John A | Reporting person | Option exercise | 1,300 | $0.00 |
| 2026-06-15 | Schmid John P. | Reporting person | Option exercise | 6,030 | $0.00 |
| 2026-06-15 | RENTON HOLLINGS | Reporting person | Option exercise | 6,030 | $0.00 |
| 2026-06-15 | Orwin John A | Reporting person | Option exercise | 6,030 | $0.00 |
| 2026-04-20 | ANAPTYSBIO, INC | Reporting person | Other acquisition/disposition | 100 | — |
| 2026-03-30 | Schmid John P. | Reporting person | Open market sale | 12,596 | $55.71 |
| 2026-03-30 | Schmid John P. | Reporting person | Open market sale | 7,527 | $56.70 |
| 2026-03-30 | Schmid John P. | Reporting person | Open market sale | 522 | $57.40 |
| 2026-03-27 | Faga Daniel | President, CEO | Open market sale | 510 | $56.61 |
| 2026-03-27 | Faga Daniel | President, CEO | Open market sale | 2,570 | $57.91 |
| 2026-03-27 | Faga Daniel | President, CEO | Open market sale | 3,662 | $58.62 |
| 2026-03-27 | Faga Daniel | President, CEO | Open market sale | 490 | $59.62 |
| 2026-03-27 | Faga Daniel | President, CEO | Open market sale | 550 | $60.63 |
| 2026-03-27 | Faga Daniel | President, CEO | Open market sale | 1,012 | $62.15 |
| 2026-03-27 | Faga Daniel | President, CEO | Open market sale | 2,592 | $63.35 |
| 2026-03-27 | Faga Daniel | President, CEO | Open market sale | 3,155 | $64.19 |
| 2026-03-27 | Faga Daniel | President, CEO | Open market sale | 3,038 | $65.20 |
| 2026-03-27 | Faga Daniel | President, CEO | Open market sale | 100 | $65.99 |
| 2026-03-25 | Faga Daniel | President, CEO | Grant / award | 34,300 | — |
| 2026-02-11 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Option exercise | 10,000 | $29.70 |
| 2026-02-11 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Open market sale | 10,000 | $54.00 |
| 2026-01-15 | Marquet Magda | Reporting person | Option exercise | 11,000 | $26.11 |
| 2026-01-15 | Marquet Magda | Reporting person | Open market sale | 9,290 | $48.12 |
| 2026-01-15 | Marquet Magda | Reporting person | Open market sale | 1,710 | $48.85 |
| 2026-01-08 | Lizzul Paul F. | Chief Medical Officer | Open market sale | 3,650 | $44.71 |
| 2026-01-08 | MULROY DENNIS | CHIEF FINANCIAL OFFICER | Open market sale | 2,515 | $44.71 |
| 2026-01-08 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Open market sale | 2,210 | $44.71 |
| 2026-01-08 | Faga Daniel | President, CEO | Open market sale | 14,281 | $44.71 |
| 2026-01-07 | Lizzul Paul F. | Chief Medical Officer | Option exercise | 8,525 | — |
| 2026-01-07 | MULROY DENNIS | CHIEF FINANCIAL OFFICER | Option exercise | 6,700 | — |
| 2026-01-07 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Option exercise | 5,888 | — |
| 2026-01-07 | Faga Daniel | President, CEO | Option exercise | 26,838 | — |
| 2026-01-07 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Open market sale | 2,017 | $45.11 |
| 2026-01-07 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Open market sale | 5,281 | $45.38 |
| 2026-01-07 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Open market sale | 1,841 | $46.13 |
| 2026-01-07 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Open market sale | 500 | $47.23 |
| 2026-01-07 | Lizzul Paul F. | Chief Medical Officer | Open market sale | 2,235 | $45.11 |
| 2026-01-06 | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | Option exercise | 5,545 | — |
| 2026-01-06 | Lizzul Paul F. | Chief Medical Officer | Option exercise | 6,145 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 15:19 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-21 | 8-K | 2026-09-21 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-03-12 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-03-12 | View on SEC.gov → |
| 2026-07-30 | 8-K | 2026-07-28 | View on SEC.gov → |
| 2026-06-22 | 8-K | 2026-06-15 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-05-29 | 8-K | 2026-05-29 | View on SEC.gov → |
Recent news
Headlines about ANAB (AnaptysBio, Inc.). Links open the publisher — we don’t host full articles.
-
AnaptysBio (NASDAQ:ANAB) Stock Price Up 5.4% - What's Next?
MarketBeat · 2026-10-21 -
AnaptysBio Shares Fall 7.74% During GSK-Tesaro Post-Trial Hearing
TOKENPOST · 2026-10-21 -
Jemperli FDA Approval Could Expand AnaptysBio Stock Royalty Potential
Simply Wall Street · 2026-10-21 -
AnaptysBio (ANAB) Shares Drop 8% Amid Delaware Breach of Contrac
GuruFocus · 2026-10-20 -
AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breach
Seeking Alpha · 2026-10-20 -
AnaptysBio, Inc. (ANAB) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
AnaptysBio Shares Rise After FDA Expands Jemperli Approval
TOKENPOST · 2026-10-20 -
AnaptysBio Shares Gain on FDA Approval for Rectal Cancer Drug
marketscreener.com · 2026-10-19
No headlines in this category right now — try “All”.